BridgeBio Pharma, Inc. (BBIO)
NASDAQ · Healthcare
BridgeBio Pharma, Inc. Long Term Debt 2019–2025
BridgeBio Pharma, Inc. annual long term debt history from 2019 to 2025. Long term debt refers to financial obligations that are due more than one year in the future.
- BridgeBio Pharma, Inc. long term debt as of December 31, 2025: 2.01B, a 358.99% increase year-over-year.
- BridgeBio Pharma, Inc. long term debt for 2025 were 2.01B, a 358.99% increase from 2024.
- BridgeBio Pharma, Inc. long term debt for 2024 were 437.3M, a 2.04% decrease from 2023.
- BridgeBio Pharma, Inc. long term debt for 2023 were 446.4M, a 3.59% increase from 2022.
- BridgeBio Pharma, Inc. long term debt for 2022 were 431.0M.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| BridgeBio Pharma, Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2025 | $2,007 |
| 2024 | $437 |
| 2023 | $446 |
| 2022 | $431 |
| 2021 | $431 |
| 2020 | $94 |
| 2019 | $95 |
BridgeBio Pharma, Inc. Long Term Debt — FAQ
BridgeBio Pharma, Inc. (BBIO) long term debt over the last 7 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BBIO's long term debt history?
The chart and table above show BridgeBio Pharma, Inc.'s long term debt by year and by quarter, including the growth rate.